Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameGBG Holdings
Stock Code08372
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities成熟醫療儀器分銷商,於香港醫療儀器市場擁有逾19年經驗,提供一站式醫療儀器解決方案,包括市場趨勢分析、醫療儀器採購、售後服務、技術支援及培訓服務、醫療儀器租賃服務及質量保證。產品分為醫療耗材、醫療設備、醫療器械及其他醫療保健產品,客戶主要包括香港公立及私立醫院、私家診所、非牟利組織、大學及個別客戶。
Listing Date2018-03-29
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)香港新界荃灣沙咀道6號嘉達環球中心29樓2901-2903室及2905室
Business Address (Hong Kong)香港新界荃灣沙咀道6號嘉達環球中心29樓2901-2903室及2905室
Place of Incorporation開曼群島
Listing Method發售以供認購 + 發售以供配售
Listing BoardGEM
Websitewww.grandbrilliancegroup.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism B
Offer PriceHK$ 0.34 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueRMB 0.01 / shares
Offer Period2018-03-19 to 2018-03-22
Global Offering Shares168,000,000 shares
HK Public Offer Shares (Initial)16,800,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)151,200,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO800,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 56,280,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 122.6M
Est. Threshold HK$ 9.39B
Analysis Result HK market cap below threshold, need +7561%

Valuation & Financials

Market Cap (at Offer Price)HK$ 268,000,000
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約11.8百萬港元
Period-End Cash Balance約9.8百萬港元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO Investment約14.1百萬港元

Financial Data

Unit: '000 HKD
Income Statement
Item 2016-032017-032017-10
Revenue 52,87651,65730,958
Cost of sales -24,688-25,631-14,752
Gross profit 28,18826,02616,206
Other income and gains, net 1167450
Selling and distribution expenses -800-795-437
Administrative expenses -12,311-11,277-6,569
Net finance costs -700
Profit before tax 15,53014,1902,024
Income tax expense -2,551-2,388-1,645
Profit for the year 12,97911,802379
Balance Sheet
Item 2016-032017-032017-10
Cash and cash equivalents 16,9229,7768,894
Trade and bills receivables 7,5417,68912,963
Inventories 14,70613,71813,957
Total current assets 40,19131,37135,814
Total current liabilities 12,6144,0869,012
Total equity 31,66531,23231,683
Cash Flow Statement
Item 2016-032017-032017-10
Net cash from operating activities 15,9084,747-3,886
Net cash from investing activities -3,901-11,646-4,078
Net cash from financing activities 240-2474,052
Net increase in cash 12,247-7,146-3,912
Depreciation of PP&E 482453160
Purchase of PP&E -113-43-1,343
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 0.4
First Day OpenHK$ 0.415
First Day Change19.40%
First Day Volume258040000.0
First Day Turnover98842200.0
Use of Proceeds
1、約6.9百萬港元(或約20.0%)將用于追加投資,拓展服務組合及加強銷售及營銷活動,以進一步滲透醫療儀器市場及提高我們在香港醫療儀器市場的市場份額; 2、約10.7百萬港元(或約30.9%)將用于招聘兩名工程師、一名登記護士、一名物理治療師、七名產品代表、兩名營銷人員、兩名研發人員、兩名信息科技技術人員、一名倉管員、一名行政人員、一名會計人員、兩名司機及兩名物流人員,擴大勞工隊伍及支付彼等直至2020年3月31日前的薪金,以應對我們業務的擴張; 3、約8.8百萬港元(或約25.4%)將部分用于近期選擇性尋求戰略收購機會; 4、約1.3百萬港元(或約3.8%)將用于加大研發及產品開發力度; 5、約2.5百萬港元(或約7.1%)將用于升級我們的資訊科技系統; 6、約2.2百萬港元(或約6.4%)將用于擴大我們的倉庫、建立展廳及升級辦公室的功能; 7、約2.2百萬港元(或約5.5%)將用作本集團的一般營運資金。

Underwriting Syndicate

Sole Sponsor (1)
国泰君安融资有限公司 CE AGS488
Overall Coordinators (1)
国泰君安证券(香港)有限公司 CE ABY236
Joint Bookrunners (2)
国泰君安证券(香港)有限公司 CE ABY236 Ruibang Securities Limited CE BIJ312
Joint Lead Managers (2)
国泰君安证券(香港)有限公司 CE ABY236 Ruibang Securities Limited CE BIJ312

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman黃碧君—
Company Secretary陳震昇—
No director data available.

Major Shareholders

Major Shareholders & Holdings黃女士及B&A Success(黃女士全資擁有)上市後持股69.68%,為控股股東;Infinite Crystal持股5.06%,由趙先生擁有61.11%權益及原先生等透過Sunstrike Investments Limited擁有38.89%權益;苗醫生為黃女士配偶,享有配偶權益。
About this page

This page shows GBG Holdings (08372) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect